Comparison between Size of OV, Fibroscan in Chronic Hepatitis C Patients Before & After Treatment with DAAs

Abstract

HCV infection is a global health issue and one of the major causes of chronic liver diseases, Egypt on the top of the countries with heavy HCV burden, HCV genotype 4 is the most common in Egypt and represents 92% of total infections. The goal of HCV therapy is eradication of the HCV which determined by sustained virological response (SVR) in order to prevent the complications which include liver fibrosis, cirrhosis, portal hypertension and hepatocellular carcinoma. The availability of direct acting antiviral drugs (DAAs) improves rates of sustained virological response (SVR). Viral eradication decreases liver damage by improving the inflammation, as well as by regressing fibrosis irrespective of the treatment regimen of DAAs. Non-invasive methods are useful in the assessment of liver fibrosis, but their usefulness for monitoring fibrosis after SVR needs to be demonstrated. Portal hypertension is a common complication of liver cirrhosis which leads to the formation of gastroesophageal varices when HVPG ≥10 mmHg which is called clinically significant portal hypertension. This aim of our study was to asses changes on the size of esophageal varices and liver stiffness after treatment of HCV with DAAs. The study was carried out at Gastroenterology and hepatology Department, Ain-Shams Hospital and Kobry-Elkoba Military Hospital and included 60 patients with chronic infection of hepatitis c